CLINICAL_TRIALS
trial_result
· 2018-12-19
Clinical Trial Update: A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas [Phase 2]
Summary
Phase 2 study of buparlisib (BKM120) in relapsed or refractory thymoma has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Patrick Joseph Loehrer Sr. | Conditions: Thymoma | Phase 2 | Status: COMPLETED | Results posted: 2018-12-19